Part 1: AI, Digital Twins, and the Future of Clinical Research‍

AI has the potential to transform clinical research. In this webinar, Charles Fisher, Founder and CEO of Unlearn.AI, will provide an overview of artificial intelligence, and its innovative uses in clinical research. He will define machine learning (ML) and introduce how proprietary ML models can generate Digital Twins, or virtual patients, in external control arms of clinical trials. Incorporating Digital Twins into clinical trials can increase statistical power, accelerate trial timelines, and enable patient level insights, elevating clinical decision making and guiding future trial design. In this webinar, you will learn about: 

  • What AI is, and its role in clinical research 
  • How novel Machine Learning approaches are used to create Digital Twins 
  • The benefits and considerations of using Digital Twins in clinical trials

THIS WEBINAR IS PART #1 OF Powering Clinical Research with AI 

Clinical trials are critical for developing new treatments, but face chronic challenges, such as optimal trial design, enrollment, costs, timeline delays, and high failure rates. The gold standard of trial design is randomization, but it is not always ethical or feasible to set up a trial where the control group receives a standard of care or a placebo. Leveraging historical data sets and novel machine learning methods, Digital Twins, or statistically indistinguishable virtual placebo patients, can be generated to match actual patients in clinical studies. Adding external control arms populated with Digital Twins, called Intelligent Control Arms, can streamline clinical trials, increase power, and decrease enrollment, without adding regulatory risk. The FDA has expressed support for innovation in trial design and alternative forms of evidence - Digital Twins are the next frontier for modern trials.

In this 3 part webinar series, you will learn about: 

  • AI and Machine Learning 
  • Digital Twins, what they are and how they are created 
  • Specific use cases for Digital Twins 
  • Trial designs and statistical approaches to increase power and accelerate timelines 
  • The regulatory landscape and support behind solutions like Digital Twins

Who should attend? 

  • Biostatisticians and statisticians 
  • Business Development/Partnerships
  • Commercial Teams Data Science Medical Directors
  • Principal Investigators
  • Clinical Research Leads
  • Regulatory Affairs

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Press

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials

Press

Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™

Blog

Success is never a straight line—reflecting on our EMA draft qualification opinion

On March 22, 2022, we reached an historic milestone with the European Medicines Agency’s release of a draft qualification opinion on our 3-step PROCOVA™ procedure.
Collaborators will leverage AI-generated Digital Twins to enable smaller, more efficient pivotal clinical trials.
Led by Insight Partners, financing builds on the company’s momentum in working with leading biopharmaceutical companies to improve clinical trial efficiency.